Methods to evaluate biliary excretion of drugs in humans: An updated review

Molecular Pharmaceutics

Volumn 3, Issue 3, 2006, Pages 198-211

  Ghibellini, Giulia ^a   Leslie, Elaine M ^a   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bile; Biliary clearance; Excretion; Hepatic transport; Hepatobiliary transport

Indexed keywords

ACETYLSALICYLIC ACID; DESLORATADINE; DICLOFENAC; DIGOXIN; EBASTINE; EPLERENONE; EZETIMIBE; FEXOFENADINE; FLUINDOSTATIN; IBUPROFEN; INDOMETACIN; IRINOTECAN; LEFLUNOMIDE; MEBROFENIN TC 99M; METHADONE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; METOCLOPRAMIDE; MIZOLASTINE; MYCOPHENOLIC ACID; PACLITAXEL; PARACETAMOL; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; VALSARTAN; VINCRISTINE;

BILE; BILE FLOW; BILIARY EXCRETION; BILIARY TRACT DRAINAGE; CELL CULTURE; CHOLECYSTECTOMY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG TRANSPORT; DUODENUM FLUID; HEPATOBILIARY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; REVIEW; T TUBE;

BILE; CELLS, CULTURED; CHOLECYSTECTOMY; CLINICAL LABORATORY TECHNIQUES; CYTOPLASMIC VESICLES; DUODENUM; FECES; HEPATOCYTES; HUMANS; INTESTINAL SECRETIONS; PHARMACOKINETICS;

EID: 33745798151     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060011k     Document Type: Review

References (157)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46 (1-3), 3-26.
2. Fleck, C.; Braunlich, H. Factors determining the relationship between renal and hepatic excretion of xenobiotics. Arzneim.-Forsch. 1990, 40 (8), 942-946.
3. Roberts, M. S.; Magnusson, B. M.; Burczynski, F. J.; Weiss, M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 2002, 41 (10), 751-790.
4. Bullingham, R. E.; Nicholls, A. J.; Kamm, B. R. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 1998, 34 (6), 429-455.
5. Jahnchen, E.; Meinertz, T.; Gilfrich, H. J.; Kersting, F.; Groth, U. Enhanced elimination of warfarin during treatment with cholestyramine. Br. J. Clin. Pharmacol. 1978, 5 (5), 437-440.
6. Pauli-Magnus, C.; Stieger, B.; Meier, Y.; Kullak-Ublick, G. A.; Meier, P. J. Enterohepatic transport of bile salts and genetics of cholestasis. J. Hepatol. 2005, 43 (2), 342-357.
7. Kullak-Ublick, G. A.; Stieger, B.; Meier, P. J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126 (1), 322-342.
8. Schwarz, U. I.; Gramatte, T.; Krappweis, J.; Oertel, R.; Kirch, W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 2000, 38 (4), 161-167.
9. Chico, I.; Kang, M. H.; Bergan, R.; Abraham, J.; Bakke, S.; Meadows, B.; Rutt, A.; Robey, R.; Choyke, P.; Merino, M.; Goldspiel, B.; Smith, T.; Steinberg, S.; Figg, W. D.; Fojo, T.; Bates, S. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J. Clin. Oncol. 2001, 19 (3), 832-842.
10. Johne, A.; Brockmoller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 1999, 66 (4), 338-345.
11. Angelin, B.; Arvidsson, A.; Dahlqvist, R.; Hedman, A.; Schenck-Gustafsson, K. Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest. 1987, 17 (3), 262-265.
12. Hedman, A.; Angelin, B.; Arvidsson, A.; Beck, O.; Dahlqvist, R.; Nilsson, B.; Olsson, M.; Schenck-Gustafsson, K. Digoxinverapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin. Pharmacol. Ther. 1991, 49 (3), 256-262.
13. Hedman, A.; Angelin, B.; Arvidsson, A.; Dahlqvist, R. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur. J. Clin. Pharmacol. 1992, 42 (5), 481-485.
14. Ding, R.; Tayrouz, Y.; Riedel, K. D.; Burhenne, J.; Weiss, J.; Mikus, G.; Haefeli, W. E. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 2004, 76 (1), 73-84.
15. Funk, C.; Pantze, M.; Jehle, L.; Ponelle, C.; Scheuermann, G.; Lazendic, M.; Gasser, R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001, 167 (1), 83-98.
16. Fattinger, K.; Funk, C.; Pantze, M.; Weber, C.; Reichen, J.; Stieger, B.; Meier, P. J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 2001, 69 (4), 223-231.
17. Rolo, A. P.; Palmeira, C. M.; Wallace, K. B. Interactions of combined bile acids on hepatocyte viability: cytoprotection or synergism. Toxicol. Lett. 2002, 126 (3), 197-203.
18. Hoffmaster, K. A.; Zamek-Gliszczynski, M. J.; Pollack, G. M.; Brouwer, K. L. R. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. 2004, 311 (3), 1203-1210.
19. Patel, N. J.; Zamek-Gliszczynski, M. J.; Zhang, P.; Han, Y. H.; Jansen, P. L.; Meier, P. J.; Stieger, B.; Brouwer, K. L. R. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol. Pharmacol. 2003, 64 (1), 154-159.
20. Manautou, J. E.; de Waart, D. R.; Kunne, C.; Zelcer, N.; Goedken, M.; Borst, P.; Elferink, R. O. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 2005, 42 (5), 1091-1098.
21. Zelcer, N.; van de Wetering, K.; Hillebrand, M.; Sarton, E.; Kuil, A.; Wielinga, P. R.; Tephly, T.; Dahan, A.; Beijnen, J. H.; Borst, P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (20), 7274-7279.
22. Nezasa, K.; Tian, X.; Zamek-Gliszczynski, M. J.; Patel, N. J.; Raub, T. J.; Brouwer, K. L. R. Altered Hepatobiliary Disposition of 5 (and 6)-carboxy-2′,7′ dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) Knockout Mice. Drug Metab. Dispos. 2006.
23. Wang, H.; LeCluyse, E. L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 2003, 42 (15), 1331-1357.
24. Ishizuka, H.; Konno, K.; Shiina, T.; Naganuma, H.; Nishimura, K.; Ito, K.; Suzuki, H.; Sugiyama, Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 1999, 290 (3), 1324-1330.
25. Zhang, P.; Swift, B. D.; Tian, X.; Brouwer, K. R. Interspecies variability of transport protein functions in sandwich-cultured (B-ClearTM) rat, dog and human hepatocytes. Drug Metab. Rev. 2005, 37 (Suppl. 2), 307.
26. Hellstem, A.; Hildebrand, M.; Humpel, M.; Hellenbrecht, D.; Sailer, R.; Madetzki, C. Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990, 28 (6), 256-261.
27. Faber, K. N.; Müller, M.; Jansen, P. L. M. Drug transport proteins in the liver. Adv. Drug Delivery Rev. 2003, 55 (1), 107-124.
28. Meier, P. J.; Stieger, B. Bile salt transporters. Annu. Rev. Physiol. 2002, 64, 635-661.
29. Kullak-Ublick, G. A.; Becker, M. B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 2003, 35 (4), 305-317.
30. van Montfoort, J. E.; Hagenbuch, B.; Groothuis, G. M.; Koepsell, H.; Meier, P. J.; Meijer, D. K. Drug uptake systems in liver and kidney. Curr. Drug Metab. 2003, 4 (3), 185-211.
31. Chandra, P.; Brouwer, K. L. R. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 2004, 21 (5), 719-735.
32. Eloranta, J. J.; Kullak-Ublick, G. A. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. 2005, 433 (2), 397-412.
33. Chiang, J. Y. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 2004, 40 (3), 539-551.
34. Mithani, S. D.; Bakatselou, V.; TenHoor, C. N.; Dressman, J. B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 1996, 13 (1), 163-167.
35. Galatola, G.; Jazrawi, R. P.; Bridges, C.; Joseph, A. E. A.; Northfield, T. C. Direct measurement of first-pass ileal clearance of a bile acid in humans. Gastroenterology 1991, 100 (4), 1100-1105.
36. Ballatori, N.; Hammond, C. L.; Cunningham, J. B.; Krance, S. M.; Marchan, R. Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 2005, 204 (3), 238-255.
37. Dawson, P. A.; Hubbert, M.; Haywood, J.; Craddock, A. L.; Zerangue, N.; Christian, W. V.; Ballatori, N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 2005, 280 (8), 6960-6968.
38. Svanvik, J. In Hepatic Transport and Bile Secretion: Physiology and Pathophysiology; Tavoloni, N., Berk, P. D., Eds.; Raven Press: New York, 1993; pp 607-618.
39. LaRusso, N. F. Gallbladder and Bile Ducts; Churchill Livingstone: Philadelphia, 1997; Vol. 6.
40. Krishnamurthy, G. T.; Krishnamurthy, S. Nuclear Hepatology: a textbook of hepatobiliary diseases; Springer: Berlin, New York, 2000.
41. Jazrawi, R. P. Review article: measurement of gall-bladder motor function in health and disease. Aliment. Pharmacol. Ther. 2000, 14 (Suppl. 2), 27-31.
42. Yamamura, T.; Takahashi, T.; Kusunoki, M.; Kantoh, M.; Seino, Y.; Utsunomiya, J. Gallbladder dynamics and plasma cholecystokinin responses after meals, oral water, or sham feeding in healthy subjects. Am. J. Med. Sci. 1988, 295 (2), 102-107.
43. Ziessman, H. A.; Muenz, L. R.; Agarwal, A. K.; ZaZa, A. A. Normal values for sincalide cholescintigraphy: comparison of two methods. Radiology 2001, 227 (2), 404-410.
44. Rehfeld, J. F.; Sun, G.; Christensen, T.; Hillingso, J. G. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J. Clin. Endocrinol. Metab. 2001, 86 (1), 251-258.
45. Beglinger, C.; Degen, L. Fat in the intestine as a regulator of appetite-role of CCK. Physiol. Behav. 2004, 83 (4), 617-621.
46. Wank, S. A. Cholecystokinin receptors. Am. J. Physiol 1995, 269 (5 Part 1), G628-G646.
47. Lave, T.; Portmann, R.; Schenker, G.; Gianni, A.; Guenzi, A.; Girometta, M. A.; Schmitt, M. Interspecies pharmacokinetic comparisons and allometric scaling of napsagatran, a low molecular weight thrombin inhibitor. J. Pharm. Pharmacol. 1999, 51 (1), 85-91.
48. Westphal, J. F.; Brogard, J. M.; Caro-Sampara, F.; Adloff, M.; Blickle, J. F.; Monteil, H.; Jehl, F. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob. Agents Chemother. 1997, 41 (8), 1636-1640.
49. Edmiston, C. E., Jr.; Suarez, E. C.; Walker, A. P.; Demeure, M. P.; Frantzides, C. T.; Schulte, W. J.; Wilson, S. D. Penetration of ciprofloxacin and fleroxacin into biliary tract. Antimicrob. Agents Chemother. 1996, 40 (3), 787-791.
50. Brune, K.; Nuernberg, B.; Schneider, H. T. Biliary elimination of aspirin after oral and intravenous administration in patients. Agents Actions Suppl. 1993, 44, 51-57.
51. Schneider, H. T.; Nuernberg, B.; Dietzel, K.; Brune, K. Biliary elimination of non-steroidal anti-inflammatory drugs in patients. Br. J. Clin. Pharmacol. 1990, 29 (1), 127-131.
52. Siegers, C. P.; Loeser, W.; Gieselmann, J.; Oltmanns, D. Biliary and renal excretion of paracetamol in man. Pharmacology 1984, 29 (5), 301-303.
53. Cheng, H.; Schwartz, M. S.; Vickers, S.; Gilbert, J. D.; Amin, R. D.; Depuy, B.; Liu, L.; Rogers, J. D.; Pond, S. M.; Duncan, C. A.; et al. Metabolic disposition of simvastatin in patients with T-tube drainage. Drug Metab. Dispos. 1994, 22 (1), 139-142.
54. Verho, M.; Luck, C.; Stelter, W. J.; Rangoonwala, B.; Bender, N. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr. Med. Res. Opin. 1995, 13 (5), 264-273.
55. Jackson, D. V., Jr.; Castle, M. C.; Bender, R. A. Biliary excretion of vincristine. Clin. Pharmacol. Ther. 1978, 24 (1), 101-107.
56. Pattinson, N. R.; Willis, K. E.; Frampton, C. M. Comparative analysis of cholesterol transport in bile from patients with and without cholesterol gallstones. J. Lipid Res. 1991, 32 (2), 205-214.
57. Lecureur, V.; Courtois, A.; Payen, L.; Verhnet, L.; Guillouzo, A.; Fardel, O. Expression and regulation of hepatic drug and bile acid transporters. Toxicology 2000, 153 (1-3), 203-219.
58. Keitel, V.; Nies, A. T.; Brom, M.; Hummel-Eisenbeiss, J.; Spring, H.; Keppler, D. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284 (1), G165-G174.
59. Trauner, M.; Wagner, M.; Fickert, P.; Zollner, G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J. Clin. Gastroenterol. 2005, 39 (4 Suppl. 2), S111-S124.
60. Shoda, J.; Kano, M.; Oda, K.; Kamiya, J.; Nimura, Y.; Suzuki, H.; Sugiyama, Y.; Miyazaki, H.; Todoroki, T.; Stengelin, S.; Kramer, W.; Matsuzaki, Y.; Tanaka, N. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function. Am. J. Gastroenterol. 2001, 96 (12), 3368-3378.
61. Pratt, D. S. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 2005, 21 (3), 270-274.
62. Pauli-Magnus, C.; Meier, P. J. Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 2005, 39 (4 Suppl. 2), S103-S110.
63. Cook, C. S.; Berry, L. M.; Bible, R. H.; Hribar, J. D.; Hajdu, E.; Liu, N. W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab. Dispos. 2003, 31 (11), 1448-1455.
64. Tse, F. L.; Jaffe, J. M.; Troendle, A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 1992, 32 (7), 630-638.
65. Anggard, E.; Gunne, L. M.; Homstrand, J.; McMahon, R. E.; Sandberg, C. G.; Sullivan, H. R. Disposition of methadone in methadone maintenance. Clin. Pharmacol. Ther. 1975, 17 (3), 258-266.
66. Karim, A.; Zagarella, J.; Hribar, J.; Dooley, M. Spironolactone. I. Disposition and metabolism. Clin. Pharmacol. Ther. 1976, 19 (2), 158-169.
67. Slatter, J. G.; Schaaf, L. J.; Sams, J. P.; Feenstra, K. L.; Johnson, M. G.; Bombardt, P. A.; Cathcart, K. S.; Verburg, M. T.; Pearson, L. K.; Compton, L. D.; Miller, L. L.; Baker, D. S.; Pesheck, C. V.; Lord, R. S., 3rd Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos. 2000, 28 (4), 423-433.
68. Martin, P. D.; Warwick, M. J.; Dane, A. L.; Hill, S. J.; Giles, P. B.; Phillips, P. J.; Lenz, E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 2003, 25 (11), 2822-2835.
69. Moller, A.; Iwasaki, K.; Kawamura, A.; Teramura, Y.; Shiraga, T.; Hata, T.; Schafer, A.; Undre, N. A. The disposition of HC-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. 1999, 27 (6), 633-636.
70. Maudgal, D. P.; Lanzini, A.; Northfield, T. C.; Bridges, C.; Joseph, A. E. Quantification of temocillin biliary excretion and gallbladder bile concentration in healthy subjects. Drugs 1985, 29 (Suppl. 5), 146-150.
71. Gundert-Remy, U.; Frohnapfel, P.; Jourdan, W.; Weber, E.; Stiehl, A. Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique. Br. J. Clin. Pharmacol. 1982, 13 (6), 795-801.
72. Janowitz, P.; Swobodnik, W.; Wechsler, J. G.; Zöller, A.; Kuhn, K.; Ditschuneit, H. Comparison of gall bladder bile and endoscopically obtained duodenal bile. Gut 1990, 31 (12), 1407-1410.
73. Northfield, T. C.; Hofmann, A. F. Biliary lipid output during three meals and an overnight fast. I. Relationship to bile acid pool size and cholesterol saturation of bile in gallstone and control subjects. Gut 1975, 16 (1), 1-11.
74. Ryde, M.; Gustavsson, S. Biliary excretion of olsalazine sodium in humans. Eur. J. Drug Metab. Pharmacokinet. 1987, 12 (1), 17-24.
75. Lanzini, A.; Pigozzi, M. G.; Wuhrer, A.; Facchinetti, D.; Castellano, M.; Bettini, L.; Guerra, U. P.; Beschi, M.; Muiesan, G. Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man. Gut 1989, 30 (1), 104-109.
76. Caldwell, J. H.; Cline, C. T. Biliary excretion of digoxin in man. Clin. Phamacol. Ther. 1976, 19 (4), 410-415.
77. von Richter, O.; Greiner, B.; Fromm, M. F.; Fraser, R.; Omari, T.; Barclay, M. L.; Dent, J.; Somogyi, A. A.; Eichelbaum, M. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther. 2001, 70 (3), 217-227.
78. Drescher, S.; Glaeser, H.; Murdter, T.; Hitzl, M.; Eichelbaum, M.; Fromm, M. F. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 2003, 73 (3), 223-231.
79. Glaeser, H.; Drescher, S.; Hofmann, U.; Heinkele, G.; Somogyi, A. A.; Eichelbaum, M.; Fromm, M. F. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin. Pharmacol. Ther. 2004, 76 (3), 230-238.
80. Tannergren, C.; Petri, N.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernas, H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 2003, 74 (5), 423-436.
81. Petri, N.; Tannergren, C.; Holst, B.; Mellon, F. A.; Bao, Y.; Plumb, G. W.; Bacon, J.; O'Leary, K. A.; Kroon, P. A.; Knutson, L.; Forsell, P.; Eriksson, T.; Lennernas, H.; Williamson, G. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab. Dispos. 2003, 31 (6), 805-813.
82. Takamatsu, N.; Kim, O. N.; Welage, L. S.; Idkaidek, N. M.; Hayashi, Y.; Barnett, J.; Yamamoto, R.; Lipka, E.; Lennernas, H.; Hussain, A.; Lesko, L.; Amidon, G. L. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm. Res. 2001, 18 (6), 742-744.
83. Ghibellini, G.; Johnson, B. M.; Kowalsky, R. J.; Heizer, W. D.; Brouwer, K. L. R. A novel method for the determination of biliary clearance in humans. AAPS J. 2004, 6 (4), e33.
84. Ghibellini, G.; Vasist, L. S.; Hill, T. E.; Bridges, A. S.; Heizer, W. D.; Brouwer, K. L. R. Determination of Piperacillin Biliary Clearance in Humans and Identification of Its Metabolites in Bile and Urine. AAPS J. 2005, 7 (S2), M1293.
85. Reynolds, K. S.; Song, M. H.; Heizer, W. D.; Burns, C. B.; Sica, D. A.; Brouwer, K. L. R. Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans. Pharm. Res. 1998, 15 (8), 1281-1285.
86. Colburn, W. A.; Vane, F. M.; Bugge, C. J.; Carter, D. E.; Bressler, R.; Ehmann, C. W. Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. Drug Metab. Dispos. 1985, 13 (3), 327-332.
87. Ezzet, F.; Krishna, G.; Wexler, D. B.; Statkevich, P.; Kosoglou, T.; Batra, V. K. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin. Ther. 2001, 23 (6), 871-885.
88. Hoglund, P.; Ohlin, M. Effect modelling for drugs undergoing enterohepatic circulation. Eur. J. Drug Metab. Pharmacokinet. 1993, 18 (4), 333-338.
89. Herman, R. J.; Van Pham, J. D.; Szakacs, C. B. Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. Clin. Pharmacol. Ther. 1989, 46 (1), 18-25.
90. LeCluyse, E. L.; Bullock, P. L.; Parkinson, A.; Hochman, J. H. Cultured rat hepatocytes. Pharm. Biotechnol. 1996, 8, 121-159.
91. Hoffmaster, K. A.; Turncliff, R. Z.; LeCluyse, E. L.; Kim, R. B.; Meier, P. J.; Brouwer, K. L. R. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm. Res. 2004, 21 (7), 1294-1302.
92. Hamilton, G. A.; Jolley, S. L.; Gilbert, D.; Coon, D. J.; Barros, S.; LeCluyse, E. L. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res. 2001, 306 (1), 85-99.
93. Annaert, P. P.; Turncliff, R. Z.; Booth, C. L.; Thakker, D. R.; Brouwer, K. L. R. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 2001, 29 (10), 1277-1283.
94. Liu, X.; LeCluyse, E. L.; Brouwer, K. R.; Lightfoot, R. M.; Lee, J. I.; Brouwer, K. L. R. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J. Pharmacol. Exp. Ther. 1999, 289 (3), 1592-1599.
95. Dunn, J. C.; Yarmush, M. L.; Koebe, H. G.; Tompkins, R. G. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J. 1989, J (2), 174-177.
96. Turncliff, R. Z.; Meier, P. J.; Brouwer, K. L. R. Effect of dexamethasone treatment on the expression and function of transport proteins in sandwich-cultured rat hepatocytes. Drug Metab. Dispos. 2004, 32 (8), 834-839.
97. Liu, X.; LeCluyse, E. L.; Brouwer, K. R.; Gan, L. S.; Lemasters, J. J.; Stieger, B.; Meier, P. J.; Brouwer, K. L. R. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 1999, 277 (1 Pt 1), G12-21.
98. Liu, X.; Brouwer, K. L. R.; Gan, L. S.; Brouwer, K. R.; Stieger, B.; Meier, P. J.; Audus, K. L.; LeCluyse, E. L. Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration. Pharm. Res. 1998, 15 (10), 1533-1539.
99. Liu, X.; Chism, J. P.; LeCluyse, E. L.; Brouwer, K. R.; Brouwer, K. L. R. Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab. Dispos. 1999, 27 (6), 637-644.
100. Chandra, P.; Lecluyse, E. L.; Brouwer, K. L. R. Optimization of culture conditions for determining hepatobiliary disposition of taurocholate in sandwich-cultured rat hepatocytes. In Vitro Cell. Dev. Biol.: Anim. 2001, 37 (6), 380-385.
101. Kostrubsky, V. E.; Strom, S. C.; Hanson, J.; Urda, E.; Rose, K.; Burliegh, J.; Zocharski, P.; Cai, H.; Sinclair, J. F.; Sahi, J. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol. Sci. 2003, 76 (1), 220-228.
102. McGinnity, D. F.; Soars, M. G.; Urbanowicz, R. A.; Riley, R. J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 2004, 32 (11), 1247-1253.
103. Ito, K.; Houston, J. B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 2004, 21 (5), 785-792.
104. Hoffmaster, K. A.; Zamek-Gliszczynski, M. J.; Pollack, G. M.; Brouwer, K. L. R. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolicaliy stable opioid peptide [D-penicillamine2,5] enkephalin. Drug Metab. Dispos. 2005, 33 (2), 287-293.
105. Kemp, D. C.; Zamek-Gliszczynski, M. J.; Brouwer, K. L. R. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol. Sci. 2005, 83 (2), 207-214.
106. Blanchard, N.; Alexandre, E.; Abadie, C.; Lave, T.; Heyd, B.; Mantion, G.; Jaeck, D.; Richert, L.; Coassolo, P. Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 2005, 35 (1), 1-15.
107. Cui, Y.; Konig, J.; Keppler, D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol. 2001, 60 (5), 934-943.
108. Sasaki, M.; Suzuki, H.; Aoki, J.; Ito, K.; Meier, P. J.; Sugiyama, Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol. 2004, 66 (3), 450-459.
109. Matsushima, S.; Maeda, K.; Kondo, C.; Hirano, M.; Sasaki, M.; Suzuki, H.; Sugiyama, Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting poiypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 2005, 314 (3), 1059-1067.
110. Kopplow, K.; Letschert, K.; Konig, J.; Waller, B.; Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 2005, 68 (4), 1031-1038.
111. Pritchard, J. B.; Miller, D. S. Expression systems for cloned xenobiotic transporters. Toxicol Appl. Pharmacol. 2005, 204 (3), 256-262.
112. Urban, T. J.; Sebro, R.; Hurowitz, E. H.; Leabman, M. K.; Badagnani, I.; Lagpacan, L. L.; Risch, N.; Giacomini, K. M. Functional genomics of membrane transporters in human populations. Genome Res. 2005.
113. Lee, W.; Glaeser, H.; Smith, L. H.; Roberts, R. L.; Moeckel, G. W.; Gervasini, G.; Leake, B. F.; Kim, R. B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. 2005,280 (10), 9610-9617.
114. Bourdet, D. L.; Pritchard, J. B.; Thakker, D. R. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 2005, 315 (3), 1288-1297.
115. Nozawa, T.; Minami, H.; Sugiura, S.; Tsuji, A.; Tamai, I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 2005, 33 (3), 434-439.
116. Zamek-Gliszczynski, M. J.; Brouwer, K. L. R. In Pharmaceutical profiling in drug discovery for lead selection; Borchardt, R. T., Kerns, E. H., Lipinski, C. A., Thakker, D. R., Wang, B., Eds.; AAPS Press: Arlington, 2004; pp 259-292.
117. Horikawa, M.; Kato, Y.; Tyson, C. A.; Sugiyama, Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab. Pharmacokinet. 2003, 18 (1), 16-22.
118. Shilling, A. D.; Azam, F.; Kao, J.; Leung, L. Use of canalicular membrane vesicles (CMVs) from rats, dogs, monkeys and humans to assess drug transport across the canalicular membrane. J. Pharmacol. Toxicol. Methods 2005.
119. Nakagomi-Hagihara, R.; Nakai, D.; Kawai, K.; Yoshigae, Y.; Tokui, T.; Abe, T.; Ikeda, T. Oatp1b1, Oatp1b3 and Mrp2 Are Involved in Hepatobiliary Transport of Olmesartan, a Novel Angiotensin II Blocker. Drug Metab. Dispos. 2006.
120. Kondo, C.; Suzuki, H.; Itoda, M.; Ozawa, S.; Sawada, J.; Kobayashi, D.; Ieiri, I.; Mine, K.; Ohtsubo, K.; Sugiyama, Y. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 2004, 21 (10), 1895-1903.
121. Letourneau, I. J.; Deeley, R. G.; Cole, S. P. Functional characterization of nonsynonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics 2005, 15 (9), 647-657.
122. Leslie, E. M.; Bowers, R. J.; Deeley, R. G.; Cole, S. P. Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1). J. Pharmacol. Exp. Ther. 2003, 304 (2), 643-653.
123. Zelcer, N.; Huisman, M. T.; Reid, G.; Wielinga, P.; Breedveld, P.; Kuil, A.; Knipscheer, P.; Schellens, J. H.; Schinkel, A. H.; Borst, P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 2003, 278 (26), 23538-23544.
124. Ozvegy, C.; Varadi, A.; Sarkadi, B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J. Biol. Chem. 2002, 277 (50), 47980-47990.
125. Leslie, E. M.; Mao, Q.; Oleschuk, C. J.; Deeley, R. G.; Cole, S. P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol. Pharmacol. 2001, 59 (5), 1171-1180.
126. Song, S.; Suzuki, H.; Kawai, R.; Sugiyama, Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab. Dispos. 1999, 27 (6), 689-694.
127. Watanabe, T.; Miyauchi, S.; Sawada, Y.; Iga, T.; Hanano, M.; Inaba, M.; Sugiyama, Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J. Hepatol. 1992, 16 (1-2), 77-88.
128. Watanabe, T.; Suzuki, H.; Sawada, Y.; Naito, M.; Tsuruo, T.; Inaba, M.; Hanano, M.; Sugiyama, Y. Induction of hepatic P-glycoprotein enhances biliary excretion of vincristine in rats. J. Hepatol. 1995, 23 (4), 440-448.
129. Karachalios, G.; Charalabopoulos, K. Biliary excretion of antimicrobial drugs. Chemotherapy 2002, 48 (6), 280-297.
130. Balant, L.; Dayer, P.; Auckenthaler, R. Clinical pharmacokinetics of the third generation cephalosporins. Clin. Pharmacokinet. 1985, 10 (2), 101-143.
131. Brogard, J. M.; Jehl, F.; Buckle, J. F.; Dorner, M.; Arnaud, J. P.; Monteil, H. Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990, 28 (11), 462-470.
132. Raber, M. N.; Newman, R. A.; Newman, B. M.; Gaver, R. C.; Schacter, L. P. Phase I trial and clinical pharmacology of elsamitrucin. Cancer Res. 1992, 52 (6), 1406-1410.
133. Mathijssen, R. H.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7(8), 2182-2194.
134. Walle, T.; Walle, U. K.; Kumar, G. N.; Bhalla, K. N. Taxol metabolism and disposition in cancer patients. Drug Metab. Dispos. 1995, 23 (4), 506-512.
135. Gidding, C. E.; Kellie, S. J.; Kamps, W. A.; de Graaf, S. S. Vincristine revisited. Crit. Rev. Oncol. Hematol. 1999, 29 (3), 267-287.
136. Ghibellini, G.; Vasist, L. S.; Heizer, W. D.; Kowalsky, R. J.; Brouwer, K. L. R. Quantitation of Tc-99m Sestamibi Biliary Excretion in Humans. Clin. Pharmacol. Ther. 2006, 79 (2), PI-48.
137. Jayasinghe, K. S.; Roberts, C. J.; Read, A. E. Is biliary excretion of paracetamol significant in man? Br. J. Clin. Pharmacol. 1986, 22 (3), 363-366.
138. Kosoglou, T.; Statkevich, P.; Johnson-Levonas, A. O.; Paolini, J. F.; Bergman, A. J.; Alton, K. B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 2005, 44 (5), 467-494.
139. Hatanaka, T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet. 2000, 39 (6), 397-412.
140. Molimard, M.; Diquet, B.; Benedetti, M. S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 2004, 18 (4), 399-411.
141. Simons, F. E.; Simons, K. J. Clinical pharmacology of new histamine H1 receptor antagonists. Clin. Pharmacokinet. 1999, 36 (5), 329-352.
142. Brookman, L. J.; Rolan, P. E.; Benjamin, I. S.; Palmer, K. R.; Wyld, P. J.; Lloyd, P.; Flesch, G.; Waldmeier, F.; Sioufi, A.; Mullins, F. Pharmacokinetics of valsartan in patients with liver disease. Clin. Pharmacol. Ther. 1997, 62 (3), 272-278.
143. Cox, P. J.; Ryan, D. A.; Hollis, F. J.; Harris, A. M.; Miller, A. K.; Vousden, M.; Cowley, H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 2000, 28 (7), 772-780.
144. Rozman, B. Clinical pharmacokinetics of leflunomide. Clin. Pharmacokinet. 2002, 41 (6), 421-430.
145. Wallemacq, P. E.; Verbeeck, R. K. Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin. Pharmacokinet. 2001, 40 (4), 283-295.
146. Hellstern, A.; Hellenbrecht, D.; Sailer, R.; Gatzen, M.; Achten, G.; Brockmann, P.; Hausleiter, H. J. Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. Eur. J. Clin. Pharmacol. 1993, 45 (5), 415-418.
147. Hedman, A.; Angelin, B.; Arvidsson, A.; Dahlqvist, R. No effect of probenecid on the renal and biliary clearances of digoxin in man. Br. J. Clin. Pharmacol. 1991, 32 (1), 63-67.
148. DeVane, C. L.; Nemeroff, C. B. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin. Pharmacokinet. 2001, 40 (7), 509-522.
149. Hucker, H. B.; Stauffer, S. C.; Balletto, A. J.; White, S. D.; Zacchei, A. G.; Arisen, B. H. Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man. Drug Metab. Dispos. 1978, 6 (6), 659-672.
150. Daneshmend, T. K.; Wamock, D. W. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. 1988, 14 (1), 13-34.
151. Verebely, K.; Volavka, J.; Mule, S.; Resnick, R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin. Pharmacol. Ther. 1975, 18 (2), 180-190.
152. Balani, S. K.; Xu, X.; Pratha, V.; Koss, M. A.; Amin, R. D.; Dufresne, C.; Miller, R. R.; Arison, B. H.; Doss, G. A.; Chiba, M.; Freeman, A.; Holland, S. D.; Schwartz, J. I.; Lasseter, K. C.; Gertz, B. J.; Isenberg, J. I.; Rogers, J. D.; Lin, J. H.; Baillie, T. A. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotrienel receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 1997, 25 (11), 1282-1287.
153. Kumar, G. N.; Jayanti, V. K.; Johnson, M. K.; Uchic, J.; Thomas, S.; Lee, R. D.; Grabowski, B. A.; Sham, H. L.; Kempf, D. J.; Denissen, J. P.; Marsh, K. C.; Sun, E.; Roberts, S. A. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 2004, 21 (9), 1622-1630.
154. Denissen, J. F.; Grabowski, B. A.; Johnson, M. K.; Buko, A. M.; Kempf, D. J.; Thomas, S. B.; Surber, B. W. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos. 1997, 25 (4), 489-501.
155. Arvidsson, A.; Alvan, G.; Angelin, B.; Borga, O.; Nord, C. E. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J. Antimicrob. Chemother. 1982, 10 (3), 207-215.
156. Bearden, D. T. Clinical pharmacokinetics of quinupristin/dalfopristin. Clin. Pharmacokinet. 2004, 43 (4), 239-252.
157. Vincent, J.; Teng, R.; Dalvie, D. K.; Friedman, H. L. Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am. J. Surg. 1998, 176 (6A Suppl.), 8S-13S.